Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Myriad Genetics Inc (NASDAQ:MYGN)

21.67
Delayed Data
As of Sep 23
 +0.17 / +0.79%
Today’s Change
19.10
Today|||52-Week Range
46.24
-49.79%
Year-to-Date
Myriad Genetics Shouldn't Overlook This Tiny Competitor
Sep 17 / MotleyFool.com - Paid Partner Content
Myriad Genetics' TruCulture Study Results Favorable
Sep 12 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close21.50
Today’s open21.33
Day’s range21.25 - 21.95
Volume1,686,867
Average volume (3 months)1,508,657
Market cap$1.5B
Dividend yield--
Data as of 3:59pm ET, 09/23/2016

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-35.68%
Earnings growth (next 5 years)+5.60%
Revenue growth (last year)+4.25%
P/E ratio12.7
Price/Sales2.98
Price/Book2.00

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...-0.24-0.62%
VIVOMeridian Bioscience ...+0.04+0.20%
NEOGNeogen Corp-0.41-0.70%
QDELQuidel Corp-0.08-0.35%
Data as of 3:59pm ET, 09/23/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)$0.26
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts

Search for Jobs